CLINICAL & PIPELINE·Drug Approval
BPI LABS Secures FDA Approval for Generic Fluorescein Sodium (ANDA220046), Expanding Injectable Portfolio
BPI LABS has received FDA approval for its generic Fluorescein Sodium injectable (ANDA220046) on April 30, 2026. This strategic move strengthens BPI LABS's presence in the generic injectable market, signaling potential shifts in procurement strategies and competitive pricing for this critical diagnostic agent. Supply chain leaders should assess new sourcing opportunities.
90-Day Activity